Skip to main content
. Author manuscript; available in PMC: 2015 Mar 20.
Published in final edited form as: Vaccine. 2010 May 26;28(0 2):B25–B31. doi: 10.1016/j.vaccine.2009.10.131

Table 2.

Immune parameters and viral outcome of both SHIV challenges in rechallenged RM1.

total ELISPOTS2 SHIV-1157ip nAb activity
SFU fold change
from 1st
challenge		 titer fold change
from 1st
challenge3 		vRNA
RAt-9
  1st challenge 3,830 130 <50
  2nd challenge 9,320 2.4× 160 1.2× <50
RSr-9
  1st challenge 5,960 160 <50
  2nd challenge 160 0.007 <10 0.06 3.3 × 106
RNu-9
  1st challenge 440 <10 <50
  2nd challenge 550 1.25× <10 - 7.4 × 106
RBa-10
  1st challenge 820 120 transient – 267
  2nd challenge 240 0.29 <10 0.08 3.8 × 106
RAr-9 (Control)
  1st challenge 0 <10 <50
  2nd challenge 5 - <10 - 7.7 × 107
1

Comparison of virus-specific ELISPOT reactivity, SHIV-1157ip nAb activity and peak plasma viremia levels at the time of 1st challenge (SHIV-1157ip) and 2nd challenge (SHIV-1157ipd3N4) from animals that were rechallenged with SHIV-1157ipd3N4. Values for the completely protected animal, RAt-9, are underlined.

2

The sum of all HIV-Tat and SIV Gag-specific ELISPOTS at the time of each challenge.

3

Where 1st challenge values were <10, the magnitude fold-change was calculated using a value of 9. adapted from Rasmussen et al. [13]